Heron Therapeutics, Inc. (HRTX) Stock Score, Valuation & Financial Research
Heron Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 21/100.
Quick answer for HRTX
Heron Therapeutics, Inc. currently has a Wall Street Score of 21/100. The stored market price is $0.32. Its financial score is 24/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Heron Therapeutics, Inc. does
Heron Therapeutics, Inc. is a biotechnology firm dedicated to creating innovative therapies for critical patient requirements. The company leverages its proprietary Biochronomer drug delivery platform, an advanced system that enables the controlled release of various short-acting pharmacological agents. This technology ensures therapeutic concentrations are maintained for periods ranging from days to weeks following just a single administration. Among its commercialized products is SUSTOL (granisetron), an extended-release injectable designed to prevent both immediate and delayed nausea and vomiting triggered by moderately emetogenic chemotherapy, or specific anthracycline and cyclophosphamide combination therapies. Additionally, Heron markets CINVANTI, an intravenous formulation of aprepitant. CINVANTI, which acts as a substance P/neurokinin-1 receptor antagonist, is indicated for the p
HRTX financial snapshot
- Wall Street Score:
- 21/100
- Current price:
- $0.32
- Market capitalization:
- $60.2M
- Revenue:
- $151.2M
- Net income:
- $-34.0M
- Free cash flow:
- $-27.9M
- Cash:
- $20.7M
- Total debt:
- $148.4M
- EPS:
- -0.12
- Financial score:
- 24/100
- Valuation score:
- 0/100
- Revenue score:
- 28/100
What stands out
- Reported year-over-year revenue growth is -0.0%.
- Free cash flow is $-27.9M, showing cash burn in the current stored period.
- The balance sheet shows $20.7M of cash versus $148.4M of total debt, so leverage deserves attention.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 24/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-08-14.
How to research HRTX
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.